Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Acadia Pharmaceuticals' forecasted revenues top $1bn in 2025. Find out why ACAD stock is a "Buy" with its profitable outlook ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 202595 patients enrolled in neoadjuvant UM trial and ...